Injury or impaired clearance of apoptotic cells leads to the pathological accumulation of necrotic corpses, which induce an inflammatory response that initiates tissue repair 1 . In addition, antigens present in necrotic cells can sometimes provoke a specific immune response [2] [3] [4] and it has been argued that necrosis could explain adaptive immunity in seemingly infection-free situations, such as after allograft transplantation or in spontaneous and therapyinduced tumour rejection 5, 6 . In the mouse, the CD8a 1 subset of dendritic cells phagocytoses dead cell remnants and cross-primes CD8 1 T cells against cell-associated antigens 7 . Here we show that CD8a 1 dendritic cells use CLEC9A (also known as DNGR-1), a recently-characterized C-type lectin [8] [9] [10] , to recognize a preformed signal that is exposed on necrotic cells. Loss or blockade of CLEC9A does not impair the uptake of necrotic cell material by CD8a 1 dendritic cells, but specifically reduces cross-presentation of dead-cell-associated antigens in vitro and decreases the immunogenicity of necrotic cells in vivo. The function of CLEC9A requires a key tyrosine residue in its intracellular tail that allows the recruitment and activation of the tyrosine kinase SYK, which is also essential for cross-presentation of dead-cell-associated antigens. Thus, CLEC9A functions as a SYK-coupled C-type lectin receptor to mediate sensing of necrosis by the principal dendritic-cell subset involved in regulating cross-priming to cell-associated antigens. We and others have recently found that the Clec9a gene encoding the CLEC9A protein is selectively expressed at high levels by the CD8a 1 subset of dendritic cells and its putative human equivalent [8] [9] [10] . To identify ligand(s) for CLEC9A, we constructed a chimaera comprising the extracellular domain of CLEC9A fused to CD3f (also known as CD247) 8 and expressed it in the T cell lines BWZ and B3Z 11 . Ligand binding to the chimaeric receptor triggers signalling via ZAP70, leading to activation of an NFAT reporter in those cells 11 . As a control, we first checked that bivalent antibodies (but not monovalent Fab fragments, see later) to CLEC9A can trigger the fusion protein CLEC9A-CD3f, in soluble form or after immobilization on plastic surfaces ( Supplementary Fig. 1 and ref. 8) . Notably, we observed basal activation of the NFAT reporter in the reporter cell lines expressing mouse or human CLEC9A-CD3f (but not expressing a control CD3f chimaera made with the related C-type lectin DECTIN-1, also known as CLEC7A), which correlated with the number of dead cells in the culture (Fig. 1a ). The addition of ultraviolet-irradiated mouse embryonic fibroblasts (MEFs) to the reporter cells induced signalling by mouse or human CLEC9A-CD3f, but not by DECTIN-1-CD3f, and this was blocked by Fab fragments of anti-mouse or anti-human CLEC9A, respectively, but not by a control Fab fragment ( Fig. 1b ). Although cells entered apoptosis shortly after ultraviolet treatment, they did not trigger CLEC9A-CD3f signalling until 4-7.5 h after irradiation, and the signal correlated with the frequency of cells that had undergone secondary necrosis during that time period, as assessed by permeability to DNA stains such as propidium iodide and TO-PRO-3 ( Fig. 1c ). All cell types tested, independently of the species of origin, induced mouse and human CLEC9A-CD3f signalling after ultraviolet-induced secondary necrosis (data not shown), indicating that the ligand is neither species nor cell-type restricted. As an independent means of measuring ligand expression, we made a recombinant version of the C-type lectin domain (CTLD) of CLEC9A, which contains the putative ligand binding site. Tetramers of CLEC9A CTLD, but not control tetramers of DECTIN-1 CTLD, stained the secondary necrotic (TO-PRO-3 1 ) fraction of MEFs that had been ultraviolet-irradiated ( Fig. 1d ). In contrast, DECTIN-1 tetramers, but not CLEC9A tetramers, stained zymosan particles ( Fig. 1d) , consistent with the role of DECTIN-1 as a b-glucan-specific receptor 12 . CLEC9A ligand exposure was seen after treatment with further primary or secondary necrosis-inducing protocols-including freezethawing, treatment with anthracyclins (mitoxantrone) or serum deprivation-and was directly proportional to the extent of TO-PRO-3 permeability induced by the treatment (Fig. 1e ). Notably, cell fixation with formaldehyde, especially when followed by detergent permeabilization, rendered the cells permeable to TO-PRO-3 and instantly revealed the ligand(s) for CLEC9A ( Fig. 1f-h ). Further analysis showed that the ligand(s) is predominantly cytoplasmic ( Fig. 1g ) and resistant to glycosidase and nuclease treatment but susceptible to the action of proteases, heat and low pH ( Fig. 1h ). We conclude that CLEC9A recognizes a ubiquitous preformed acid-labile proteinassociated ligand(s) that is normally sequestered in healthy cells but becomes exposed during necrosis, after loss of membrane integrity.
To test for a role of CLEC9A in mediating responses to necrotic cells, we generated Clec9a gfp/gfp mice in which CLEC9A expression is abrogated by the insertion of a gene encoding a membrane-anchored form of green fluorescent protein (GFP) into the Clec9a open reading frame ( Supplementary Fig. 2a ). CD8a 1 dendritic cells from these mice, as well as the CD8a 1 dendritic-cell-like (CD24 hi CD11b lo B220 neg ) 13 subset from FLT3L-derived bone marrow cell cultures (FLT3L-BMDC), did not stain for CLEC9A but did express GFP ( Supplementary Figs 2b, c and 3a ). All other leukocytes were GFPnegative ( Supplementary Fig. 2b and data not shown), consistent with the restricted expression of high levels of the Clec9a gene to CD8a 1 dendritic cells 8, 10 . Dendritic cell phenotype and numbers were unaltered in Clec9a gfp/gfp mice indicating that CLEC9A is not essential for dendritic cell development ( Supplementary Fig. 2b-d) , and the response of dendritic cells to innate stimuli was not altered by the loss of CLEC9A ( Supplementary Figs 2f and 3b ). No alterations were found in leukocyte numbers or frequencies in spleen, lymph node or thymus ( Supplementary Fig. 2b -e and data not shown), and the Clec9a gfp/gfp mice appeared normal and did not develop any obvious symptoms of autoimmune disease (data not shown).
We first tested whether CLEC9A is necessary for the engulfment of dead cells. Using a conventional flow cytometry assay, CLEC9A 1 and CLEC9A-deficient CD8a 1 -like dendritic cells from FLT3L-BMDC cultures were seen to acquire equivalent amounts of material from dye-labelled secondary necrotic splenocytes over a similar time period ( Fig. 2a and Supplementary Fig. 4 ). We confirmed that CLEC9Adeficient CD8a 1 -like dendritic cells are not impaired in their ability to phagocytose necrotic cell material in vitro using multispectral imaging flow cytometry, which differentiates between surface binding and particle internalization ( Fig. 2b) . Notably, CLEC9A deficiency also did not impair uptake of cellular material by spleen CD8a 1 dendritic cells in vivo after the injection of necrotic cells into mice ( Fig. 2c ). We therefore assessed whether CLEC9A might be necessary for steps subsequent to necrotic cell ingestion, culminating in the cross-presentation of dead-cell-associated antigens to CD8 1 T cells. Ultraviolet-treated congenic (H-2 bm1 ) transformed MEFs untransfected (bm1 T) or transfected to express a non-secreted ovalbumin (OVA)-GFP fusion protein (bm1 T OVA) were allowed to undergo secondary necrosis and were then added to control (CLEC9A 1 ) or Clec9a gfp/gfp CD8a 1 -like dendritic cells purified from FLT3L-BMDC cultures, together with OVA-specific OT-I T-cell receptor transgenic CD8 1 T cells. Notably, CLEC9A-deficient CD8a 1 -like dendritic cells showed a reduced ability to support OT-I expansion and differentiation into IFN-c-producing effector cells, a readout for the crosspresentation of OVA ( Fig. 2d, e ). In contrast, when the antigen was offered in the form of a soluble protein or as a conjugate to latex beads, CLEC9A-deficient CD8a 1 -like dendritic cells were comparable stimulators to CLEC9A 1 dendritic cells, indicating that CLEC9A deficiency does not intrinsically impair cross-presentation ability ( Fig. 2d , e). Therefore, CLEC9A is not required for the uptake of necrotic cell material but is necessary for efficient cross-presentation of dead-cellassociated antigens by CD8a 1 dendritic cells.
The CLEC9A cytoplasmic tail contains a hemITAM motif 14 with a tyrosine at position 7, which allows binding of SYK kinase after phosphorylation ( Supplementary Fig. 5a ) 9 . Consistent with those data, monoclonal antibody-mediated crosslinking of CLEC9A induced phosphorylation of endogenous SYK in a CLEC9A-transfected B cell line ( Supplementary Fig. 5b ) and promoted activation of NFAT in B3Z cells, which was dependent on the co-expression of SYK and the presence of Tyr 7 in CLEC9A ( Supplementary Figs 5c and 6) . Similarly, necrotic cells triggered CLEC9A signalling in a SYK-and Tyr 7-dependent fashion ( Supplementary Fig. 7a , b) independently of phagocytosis (data not shown). To address the role of signalling in dendritic cells, we first assessed whether SYK is activated in response to necrotic cells. CD8a 1 -like dendritic cells incubated with dead cells showed phosphorylated SYK at the interface between the dendritic cells and the corpse, which was significantly decreased when using CLEC9A-deficient cells (Fig. 3a ). We then reconstituted dendritic cells from Clec9a gfp/gfp mice with wild-type CLEC9A or the Y7F signallingdeficient mutant by retroviral transduction. Ectopic expression of the wild-type receptor restored the ability of the CD8a 1 -like dendritic cells to efficiently cross-present dead-cell-associated OVA, confirming that the deficiency observed in the CLEC9A-deficient cells is not due to a secondary defect unrelated to CLEC9A ablation (Fig. 3b, c) . In contrast, cells transduced with the signalling-deficient receptor behaved as CLEC9A-negative control cells transduced with a virus lacking the insert and showed a profound deficiency in the cross-presentation of dead-cell-associated OVA (Fig. 3b, c) . In all cases, dendritic cells crosspresented bead-associated OVA with equal efficiency (Fig. 3b, c) , again indicating the selectivity of CLEC9A for dead-cell-associated antigens. We therefore assessed the ability of SYK-deficient dendritic cells to cross-present such antigens. As for CLEC9A-deficiency, loss of SYK did not impair the uptake of dead cells by CD8a 1 -like dendritic cells ( Supplementary Fig. 8a) but blocked cross-presentation of dead-cellassociated OVA, but not soluble OVA, to OT-I T cells ( Supplementary  Fig. 8b and data not shown) 15 . Thus CLEC9A signalling via SYK kinase is required for cross-presentation of dead-cell-associated antigens by CD8a 1 dendritic cells. Furthermore, to assess the importance of CLEC9A in the crosspresentation of necrotic cell-associated antigens in vivo, we used a cross-priming model that relies on the intrinsic immunogenicity of dead cells to induce CTL responses to associated antigens [2] [3] [4] [16] [17] [18] . We immunized Clec9a gfp/gfp mice and littermate controls with ultraviolettreated bm1 T OVA cells undergoing secondary necrosis and measured anti-OVA responses 6 days later. In CLEC9A 1 mice, these dead cells induced robust CD8 1 T cell cross-priming as measured by specific tetramer staining or by the production of IFN-c in response to ex vivo spleen cell restimulation with OVA peptide (Fig. 4a-c) . Notably, cross-priming was significantly diminished in Clec9a gfp/gfp mice when compared to littermate controls across all litters tested ( Fig. 4a-c) . To exclude the possibility that CLEC9A-deficient mice have an altered T cell repertoire, we sought to confirm these results in wild-type animals. We found that soluble anti-CLEC9A antibodies block the ability of dead cells to trigger mouse CLEC9A signalling ( Supplementary Fig. 7) , and we therefore treated C57BL/6 mice with anti-CLEC9A monoclonal antibody and measured cross-priming to dead cells expressing OVA. Anti-CLEC9A but not an isotype-matched control antibody reduced cross-priming to bm1 T OVA (Fig. 4d, e and Supplementary Fig. 9 ). The effect of antibody blockade was consistently more marked than that of genetic ablation ( Fig. 4 and data not shown), perhaps because of redundancy in CLEC9A-deficient mice, incomplete backcrossing to the C57BL/6 strain and/or because the antibody promotes clearance of a complex of CLEC9A and other receptors involved in cross-priming to dead-cell-associated antigens. Thus, CLEC9A is necessary in vivo for efficient cross-priming to antigens associated with dead cells.
Here we describe CLEC9A as a CD8a 1 dendritic-cell-expressed receptor for necrotic cells that regulates the cross-presentation of dead-cell-associated antigens by means of signalling via SYK kinase. Despite the fact that CLEC9A is an endocytic receptor 8, 9 , it does not seem to function in particle phagocytosis 9 and, like SYK, is dispensable for the uptake of necrotic cell fragments. Rather, CLEC9A and SYK have a non-redundant role at a subsequent step(s) required for cross-presentation of dead-cell-associated antigens. We find that antibodies against CLEC9A are not delivered to lysosomal compartments upon endocytosis, unlike antibodies to CD205 (also known as LY75) ( Supplementary Fig. 10a ) 19 , and that CLEC9A co-localizes exclusively with the non-lysosomal fraction of necrotic cell material internalized by CD8a 1 dendritic cells ( Supplementary Fig. 10b ). Thus, we favour a model in which CLEC9A, like the mannose receptor 20 , diverts cargo away from lysosomal compartments to allow retrieval of antigens for cross-presentation. Because CLEC9A seems to be an activating receptor 9,10 , similar to DECTIN-1 (ref. 21) , the CLEC9A-SYK pathway may also act to activate dendritic cells in response to dead cells, either autonomously 22 or in collaboration with Toll-like receptors 18, 23, 24 . Notably, as predicted by the 'danger' model 5 , CLEC9A is involved in translating innate recognition of dead cells into adaptive immunity after recognition of a preformed cellular ligand(s) that becomes exposed upon necrosis. Nevertheless, we cannot exclude the possibility that CLEC9A is also involved in cross-tolerance to dead-cell-associated antigens. Whichever the case, LETTERS downstream of CLEC9A, our data also implicate the SRC family kinase and the SYK axis as mediators of dead cell recognition by the innate immune system. Notably, orthologues of SRC and SYK mediate clearance of apoptotic and necrotic cells by Drosophila glial cells 25 , and another SYK-coupled C-type lectin was recently shown to promote inflammatory responses to necrotic cells 26 . Thus, CLEC9A may be one of a family of SYK-coupled receptors that tap into an evolutionarily ancient mechanism for recognizing cell death.
METHODS SUMMARY
Mice. The generation of the Clec9a knockout mice is described in the Supplementary Methods. Clec9a 1 and Clec9a gfp/gfp mice were on a mixed 129/Sv 3 C57BL/6 genetic background at the third generation of backcrossing to C57BL/ 6. All experiments and analyses were carried out using littermate comparisons. Figure 4 | CLEC9A is necessary for cross-priming to dead-cell-associated antigens in vivo. a-c, Clec9a gfp/gfp (CLEC9A 2 ) or control Clec9a 1/1 or Clec9a gfp/1 (CLEC9A 1 ) littermates were immunized i.v. with 7.5 3 10 5 UVC-treated bm1 T OVA MEFs. Six days later, the frequency of OVAspecific CD8 1 T cells was determined in the spleen (a, b). Each dot in a corresponds to an individual mouse; the data are pooled from seven independent experiments. The average response in each litter is shown in b with lines linking sex-matched (female) littermates. c, IFN-c production in response to OVA peptide restimulation ex vivo. Data indicate the frequency of IFN-c 1 cells within the CD8 1 T cell population. Data show individual mice and the average response from three different litters. d, e, C57BL/6 mice untreated (2) or treated with anti-CLEC9A antibody or an isotypematched control (IgG1) were immunized i.v. with 7.5 3 10 5 UVC-treated bm1 T OVA MEFs. The frequency of OVA-specific CD8 1 T cells (d) or of IFN-c producing CD8 1 T cells (e) in response to OVA peptide restimulation was measured 6 days later. Individual mice and the average for one representative experiment out of three are shown. P values were determined using the Student's t-test (paired for b).
